The landscape for Alzheimer’s disease is rapidly changing. This episode of tHEORetically speaking features Dr. Carl Marci from OM1 and Dr. Luke Stoeckel from NIA, as they discuss the critical need for earlier detection leading to potentially life changing earlier interventions. Continue Reading
In this interview with Chad Rose, General Manager of hēRo3, he explains how biopharma is incorporating critical HEOR insights into decision-making for early pipeline assets. Why is there a need to revolutionize the way HEOR insights are used in the… Continue Reading
Precision medicine and value-based care are buzzwords used over the last two decades. At inception, these principles were seen as two opposing forces in the fight against cancer. Now, industry leaders view precision medicine and value-based care as two sides… Continue Reading
The current healthcare environment reshapes the three key factors in market access – value, evidence, and commercial positioning of new treatments. Greater emphasis on patient centricity meets budget cuts. Leading to a sharper focus on demonstrating patient benefit value specific… Continue Reading
